PI3K inhibitors approved for indications involving relapsed to refractory indolent non-Hodgkin lymphoma or chronic lymphocytic leukemia include idelalisib, copanlisib, duvelisib, and umbralisib.
These inhibitors work on the PI3K Delta isoform.
Alpelisib is approved for breast cancer and PIK3CA- related overgrowth spectrum.
Side effects of this drug class include fatal or serious infections, neutropenia, and immuno mediated toxic side effects such as diarrhea, colitis, hepatotoxicity, pneumonitis, and dermatological toxicity.
PI3K alpha isoform can cause hyperglycemia and hypertension.
Immune mediated toxicities A partly attributed to decreased regulatory T – cell activity.
As single agents serious adverse reactions have been observed and up to 65% of patients and severe adverse reactions in up to 85%.
Adverse side effects reduced her ability in frequently lead does interruptions, reductions come or permanent discontinuation of these agents.